Year None202220212020201920182017

November 9, 2022

Albireo to Participate in Jefferies London Healthcare Conference

November 8, 2022

Albireo Reports Q3 2022 Financial Results and Business Update

November 7, 2022

Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types

November 3, 2022

Albireo Announces 2022 SPARK Grant Winners

November 2, 2022

Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia

November 1, 2022

Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022

October 31, 2022

Albireo to Report Q3 2022 Financial Results on November 8, 2022

October 13, 2022

Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NASPGHAN

October 12, 2022

Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

October 11, 2022

Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Alagille Syndrome

• Email Alerts
• RSS
• Print